NCT00688207View on ClinicalTrials.gov

Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Alzheimer's Disease
Interventions
DRUG

Rosiglitazone (Extended Release)

open-label, single, oral, 4mg dose

Trial Locations (1)

10117

GSK Investigational Site, Berlin

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00688207 - Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR) | Biotech Hunter | Biotech Hunter